Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials

This publication has 42 references indexed in Scilit:

• Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors
  Transplantation, 2004
• Measuring inconsistency in meta-analyses
  BMJ, 2003
• Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients
  Transplantation, 2003
• A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation
  Transplant International, 2002
• High‐dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients
  Transplant Infectious Disease, 1999
• Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation
  New England Journal of Medicine, 1999
• Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients
  Transplant International, 1997
• Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients
  Transplant International, 1994
• Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults
  Journal of Medical Virology, 1993
• A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts
  New England Journal of Medicine, 1989